What is an optimal stent? Biological requirements of drug eluting stents by Camici, G G
University of Zurich
Zurich Open Repository and Archive
Winterthurerstr. 190
CH-8057 Zurich
http://www.zora.uzh.ch
Year: 2008
What is an optimal stent? Biological requirements of drug
eluting stents
Camici, G G
Camici, G G (2008). What is an optimal stent? Biological requirements of drug eluting stents. Kardiovaskuläre
Medizin, (1):22-25.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Kardiovaskuläre Medizin 2008, (1):22-25.
Camici, G G (2008). What is an optimal stent? Biological requirements of drug eluting stents. Kardiovaskuläre
Medizin, (1):22-25.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Kardiovaskuläre Medizin 2008, (1):22-25.
Cardiovascular Biology Prize 2007 Kardiovaskuläre Medizin 2008;11: 22–25
22
Giovanni G. Camici
Cardiovascular Center, University
and University Hospital, Zürich
Center for Integrative Human Physiology,
University of Zürich
What is an optimal stent?
Biological requirements
of drug eluting stents
Summary
Although drug eluting stents (DES) have been
successful in preventing neointima formation
thereby decreasing the rates of restenosis, se-
veral concerns remain about the incidence of
stent thrombosis – a rare complication associa-
ted to highmortality. For this reason, much ef-
fort is being made in searching for new mole-
cules and approaches to develop innovative
DES able to inhibit restenosis as well as de-
creasing the incidence of late stent thrombo-
sis. Second generation DES have recently en-
tered daily clinical practice but definitive data
concerning their efficacy are not available yet.
Still, the close relationship between agents
used on first generation DES and those em-
ployed in second generation DES gives us rea-
son to speculate that more efforts are needed
in order to make concrete advances. This re-
view article focuses on the existing problems
of currently availableDES as well as the inno-
vations needed in order to improve further the
outcome of stent implantation. Present time
efforts should be directed towards identifying
multi-coatings to be applied on inert polymers
so as to have targeted approaches for each of
the therapeutical requirements of a stented
coronary artery. An ideal stent should locally
inhibit vascular smooth muscle cells prolif-
eration, enhance endothelial healing through
improved endothelial progenitor cells function
and ultimately prevent platelets activation.
Current technology seems to offer individual
alternatives for all these requirements; so the
“perfect stent” should be soon available.
Introduction
Percutaneous coronary intervention (PCI) is a
routine procedure performed to revascularise
occluded coronary arteries of patients which
suffered an acute myocardial infarction. Fol-
lowing revascularisation, stents – cylinder-
like structures designedwith the intent of pre-
venting or delaying vessel re-narrowing – are
routinely inserted in the vessel.At first, stents
were considered as mere physical impedi-
ments to prevent restenosis; however in the
last decade stents were exploited as true reser-
voirs for the local release of specific drugs at
the site of injury. This novel concept enabled
the coating of stents with drugs, such as siro-
limus designed to interfere with cell cycle pro-
gression to inhibit the excessive proliferation
and migration of vascular smooth muscle cells
(VSMC) taking place after stent deployment.
Drug eluting stents (DES) proved extremely
successful in reducing restenosis rates from
the 20–30% range, as observed with bare
metal stents (BMS) to single digits [1]. Never-
theless, the frequency of stent thromboses
(fig. 1) has not decreased as compared to BMS
[2].
As recently reported at the congress of the
American Heart Association, rate of cardiac
death and non-fatal myocardial infarctions
has unexpectedly increasedwith the advent of
DES as compared to BMS (table 1).
For this reason, stent thrombosis – a rare
but severe complication occurring after stent
implantation – remains a major concern in
contemporary clinical practice where DES are
employed [3]. Such clinical scenario prompted
several investigators to seek possible explana-
tions to the lasting occurrence of stent throm-
boses.Much emphasis has been put on the pos-
sible undesired effects caused by the different
coatings and eluted agents used in DES [4–6].
Limited information are available about
the pathogenesis of stent thrombosis [7] how-
ever, a recent study identified several key ob-
servations, including: (1.) DES show delayed
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healing as well as reduced reendothelialisa-
tion compared with BMS (p = 0.0001); and (2.)
other factors associatedwith late stent throm-
bosis include local tissue hypersensitivity re-
actions, and stent specific adverse reactions
[8].
DES proved to impair the healing process
which normally begins as result of mechanical
injury, after stent implantation.A recent study
of 48 matched DES-BMS patients revealed
that reendothelialisationoccurred in only 56%
of the DES cases compared with 90% of the
BMS cases. This finding was underlined by
higher fibrin depositions which reveal delayed
healing caused by inflammation in the DES-
treated lesions. In addition, 61% of the DES
cases showed signs of late stent thrombosis
comparedwith only 8% of the BMS cases [9]
(fig. 2).
Several lines of evidence demonstrated
that the observed delay in reendothelialisation
may be due to the unspecific nature of the an-
tiproliferative agents eluted byDES. In fact, it
is likely that agents released from DES do not
only affect proliferation and migration of
VSMC, but also that of endothelial cells. This
hypothesis was later confirmed by two studies
showing that both rapamycin and paclitaxel
besides inhibitingVSMC proliferation, also in-
hibit endothelial cell proliferation and migra-
tion [4, 10] thus, probably impairing reen-
dothelialisation and leaving the thrombogenic
stent struts exposed to circulating platelets
and coagulation factors (fig. 2).Although these
results may not accurately represent the fate
of patients who receive DESand survive, they
do show that the natural healing process after
DES implantation is not as optimal as origi-
nally hypothesised. In consideration of the
above, an optimal stent should release agents
aimed at suppressing VSMC proliferation
without impairing endothelial cells function.
Seemingly this could be achievedwith existing
compounds, such as tacrolimus that differen-
tially affects VSMC and endothelial cells pro-
liferation and thus should be considered for
novel combined applications [11]. In addition
to sparing endothelial cells proliferation, an
optimal stent should be conceived using inert
coatings which do not elicit local inflammation
as previously illustrated [8] but rather offer a
plain surface which diminishes platelet adhe-
sion and fibrinogen binding as compared to
BMS [12].
An additional limitation of contemporary
DES is represented by the lack of a strategy
aimed at enhancing endothelial progenitor
cells (EPCs) function. Several studies under-
lined the fundamental role of EPCs in the
process of reendothelialisation taking place
following PCI [13, 14] hence, current DES
should be conceptualised with the intent of
stimulating EPCs function. Paradoxically, ra-
pamycin was recently shown to inhibit prolif-
eration, migration, and differentiation of hu-
man EPCs in vitro and thus probably account-
ing at least in part, for the lack of reendothe-
lialisation observedwithDES [15, 16]. In light
of this finding, the decreased rate of reendo-
thelialisation recently reported inDES compar-
ed toBMS becomes less surprising [9]. In keep-
ing with this problem, an innovative approach
was lately describedwhereby stents struts are
loaded with integrin-binding peptides so as to
limit coronary neointima formation and, at the
same time accelerate reendothelialisation by
attracting EPCs [17]. Results from this study
Figure 1
Human artery showing a
complete occlusion caused
by stent thrombosis (left)
and, cartoon depicting early
phases of platelet recruit-
ment at the site of the le-
sion within the stented seg-
ment. Website: www.gary
ferster.com (right).
Figure 2
In-growth of tissue may
cause BMS to become ob-
structed, resulting in the
need for a second proce-
dure. DES inhibit this pro-
cess, but uncovered stent
struts may be prone to
thrombosis after discontinu-
ation of antiplatelet therapy.
(Shuchmann M. Debating
the risks of drug-eluting
stents. N Engl J Med.
2007;356(4):325–8.
Copyright© 2008
Massachusetts Medical
Society. All rights reserved.)
Table1
Outcome comparison between BMS and DES. (Presented by
Pfisterer ME at the American College of Cardiology 2006.)
Outcome Bare-metal DES (%) p
stent (%)
Cardiac death 0 1.2 0.09
NonfatalMI 1.3 4.1 0.04
Cardiac death / 1.3 4.9 0.01
nonfatalMI
Restenosis-related 6.7 4.5 0.21
TVR
MACE 7.9 9.3 0.53
MI = myocardial infarction; TVR = target vessel
revascularisation;MACE = major adverse
cardiac events.
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showed enhanced endothelial coverage on
stents loaded with integrin-binding peptides
at four weeks associated with a significant in-
crease in the early recruitment of infused
EPCs [17]. Although long term data on the ef-
ficacy of these stents are not available yet, in-
tegrin-binding peptides loaded stents may be
useful for reducing in-stent restenosis by ac-
celerating reendothelialisation and, may
prove a winning formula in the near future.
Thrombosis is principally driven by tissue
factor (TF) – the crucial initiator of the coagu-
lation cascade. Intuitively, modern stents
should be designed so as to locally reduce the
expression of TF protein thus minimising the
risks of stent thrombosis. Paradoxically, inde-
pendent reports recently described that both
rapamycin and paclitaxel enhance expression
and activity of TF under inflammatory condi-
tions [4–6]. This surprising finding represents
a real threat especially when considering that
agents used on second generation DES ie
everolimus and zotarolimus, are structurally
very closely related to rapamycin and thus give
us reason to expect similar unwanted side ef-
fects. Such scenario is surely symptomatic of a
lack of sufficient progress.
In this challenging setting, a novel alter-
native was recently illustrated whereby dime-
thyl sulfoxide (DMSO) may represent an inter-
esting therapeutic principle for DES. DMSO
was shown to inhibit VSMC proliferation and
migration while heavily blunting TF expres-
sion in endothelial cells, VSMC, and monocy-
tes. Additionally, intraperitoneal application
of DMSO in vivo prevented thrombotic occlu-
sion in a mouse model of photochemical caro-
tid artery injury. Such data attract much at-
tention especially in view of a possible additio-
nal effect of DMSO as an antiplatelet agent
[18]. Consequently, DMSO may hold some of
the criteria that agents eluted from modern
DES should meet. Nevertheless more insights
on higher animal models and humans will be
needed before considering possible clinical ap-
plications.
Conclusion
The optimalDESwill be coatedwith a simple-
structure neutral polymerwhich doesnot elicit
local inflammatory responses and does not
favour platelet adherence.Additionally, it will
inhibit restenosis throughaVSMC-specifican-
tiproliferative effect whichwill spare endothe-
lial cells.More emphasis will be put on the role
of EPCs thus, the optimal stent will be coated
with peptide-binding integrins [17] or antibod-
ies [19] which will enhance EPCs retrieval
thus facilitating reendothelialisation. Ideally,
future stents should also target local pro-
thrombotic factors such as TF. In this direc-
tion, the optimal stent will be releasing anti-
TF agents such as orwith similar properties to
DMSO which will contribute to maintaining
local haemostasis on top of having synergistic
effects to antiproliferative agents used on the
same stent. The optimal stent will have the
“right drug for the right condition” approach
and will hence release a multitude of agents
which will maintain local homeostasis intact
(fig. 3).
The “Optimal Stent”
Tissue Factor
TF/FVII
Coagulation
Cascade
Fibrin
Thrombus
EPC Recruitment
EC ProliferationVSMC Proliferation
Figure 3
Requisites of the optimal
stent.
EPC = endothelial progeni-
tor cells; VSMC = vascular
smooth muscle cells;
EC = endothelial cells.
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